News | December 21, 2025
Alvotech, Teva secure US settlement with Regeneron for Eylea biosimilar launch
Under the agreement, AVT06 is licensed to enter the US market in the fourth quarter of 2026
Under the agreement, AVT06 is licensed to enter the US market in the fourth quarter of 2026
The seminar aimed to raise public awareness about inflammageing—chronic, low-grade inflammation that silently damages the body and accelerates ageing
Takeda said zasocitinib was generally well tolerated, with a safety profile consistent with earlier studies
Efdoralprin alfa, a recombinant human alpha-1 antitrypsin (AAT)-Fc fusion protein, showed superior efficacy to standard plasma-derived therapy in adults with AATD
USFDA determines Sun Pharma's Baska facility inspection classification as OAI
Travoprost ophthalmic solution is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension
The funding will support the pivotal Phase 3 clinical trial of neridronate in CRPS-1
The expansion includes a larger technical and service team and increased local procurement
If cleared by regulators, CagriSema would become the first treatment to combine a GLP-1 receptor agonist and a long-acting amylin analogue in a single injection
The EIR was issued following an inspection of the facility from September 8 to September 16, 2025
Subscribe To Our Newsletter & Stay Updated
